This product is designed to provide many of the essential nutrients required for balanced nervous system function. The purpose is to not only keep the nervous system healthy, but to positively affect all illness that is in any way dependent on neural innervation or secretion.
The immediate impact of ElectroForm will be to stabilize electro-chemical events associated with neural transmission. Long term results include the enhancement of neurotransmitter synthesis, storage and secretion, a gradually increasing flow of blood to the brain, enhanced free-radical neutralization, and improvement in the health of neural tissue itself.
Since the proper functioning of the nervous system is paramount to the maintenance of health throughout the body, the consumption of this product should be an early priority in the intervention program. In the absence of immediate neural disease, large doses of ELECTROFORM are not usually necessary.
The use of ELECTROFORM is highly recommended for persons subject to a great deal of daily stress, women suffering from PMS, and children with behavioral disorders.
B. Patient Reactions
Expect improved mood, memory, sleep habits, alertness and general improvement in overall health. Decreased anxiety, nervousness, fatigue, cramps, tension, stress, symptoms of PMS, and related conditions.
Alzheimer's and Parkinson's patients may respond favorably to ELECTROFORM, but only with extended treatment.
ELECTROFORM should be considered for application whenever CYBERFORM, HORMONOFORM and REGENOFORM are used. It is not contraindicated even for persons driving heavy equipment; on the contrary, it will increase the alertness and reaction time in such persons by removing the tension that normally attends such activity, especially during the winter when road conditions are difficult.
C. Notes on Constituents
1. Critical for proper neural transmission by insuring proper release of neurotransmitter from synaptic vesicles; deficiency results in hypersensitivity, whereas high concentrations can depress nerve irritability.
2. Transmitters affected are serotonin, acetylcholine and norepinephrine.
3. Facilitates ACH synthesis by activating the enzyme choline acetylase in synaptic vesicles.
4. Along with magnesium, is directly responsible for activating contractions in striated and smooth muscles.
5. Activates the enzyme glycogen phosphorylase kinase which triggers glycogenolysis which in turn supplies glucose-6-P for use in energy production.
6. Acts in conjunction with magnesium as a natural tranquilizer.
1. Plays a vital role in nervous system health as it is required in the synthesis of choline, the precursor to the neurotransmitter acetylcholine.
2. Has been called "crucial to mental and emotional health."
3. Deficiency produces irritability, forgetfulness, and mental sluggishness.
4. Especially needed in supplement form by women using the pill.
5. Essential to the formation of RNA; facilitates the use of RNA, and can help normalize brain wave abnormalities.
1. Essential for the conversion of choline to acetylcholine.
1. Along with calcium, essential for proper nerve transmission.
2. Acts in conjunction with calcium as a natural tranquilizer.
3. Affects mental performance.
4. An increase in tissue fluids can increase the amount of neurotransmitter substances stored in the brain.
5. Required for proper assimilation of calcium.
1. Required for proper assimilation of calcium.
2. Is a cofactor for cytochrome C, important in electron transport and energy production.
1. Essential to the function of two enzyme systems in the brain and certain other organs of the body, including lung, muscle and spleen: (1) catalytic role of xanthin oxidase in uric acid formation; (2) the aldehyde oxidase role in oxidation of various aldehydes.
2. Promotes normal growth and development, and normal cell function.
1. Functions as a building block for all proteins.
2. Stimulates the activity of human-growth hormone.
Medicago sativum (Alfalfa)
1. Helps repair and heal connective tissues, muscles, neural tissue and bones.
2. A source of concentrated nutrition, containing a host of minerals, vitamins and other substances, in a form that is easily digested and assimilated by man.
3. Contains up to 50% protein, a good quantity of beta-carotene, chlorophyll and octacosanol, saponins, sterols (beta- sitosterol, stigmasterol and alpha-spinasterol), flavonoids, coumarins, alkaloids, acids, vitamins (A,B1,B6,B12,C,D,E,K, niacin, pantothenic acid, biotin, folic acid), amino acids, sugars, minerals (calcium, phosphorous, potassium, magnesium, iron, zinc and copper), trace elements and other nutrients.
4. Reputed to be a neural tonic, kidney tonic, liver tonic, "superlative restorative tonic," digestive tonic, prostatic tonic, reproductive tonic, musculoskeletal tonic, and overall glandular tonic.
1. Stimulates growth in animals, as measured by gain in body weight; probable enhancement of hypothalamic norepinephrine levels which has been associated with increased feeding behavior in animals; probably due to ferulic acid component of molecule.
2. In humans, supplementation with gamma oryzanol has been more successful than anabolic steroid use in maintaining muscle girth gains from weight training programs; furthermore, it consistently produces greater energy during workouts, slimmer waists, greater strength, reduction of fat, increase in lean muscle mass.
3. Possess considerable anti-oxidant activity, much like vitamin E and selenium; due to ferulic acid moiety.
4. Has anti-cancer, lipotropic, anti-ulcer, anti-stress and pro-endocrinological effects.
1. A good source of copper, calcium, manganese, magnesium, most B vitamins, octacosanol, phosphorous and vitamin E, all of which are utilized or play a role in the maintenance, repair and growth of neural tissues.
2. May help improve physical stamina and endurance.
3. Has been used to treat muscular dystrophy.
Gycyrrhiza glabra (Licorice) Root
1. Through its tonic action on the adrenal glands, helps to insure the availability of adrenergic transmitter substances and precursors.
2. Helps to regulate the electrolytes involved in neural transmission through a mineralcorticoid-like action.
1. Closely allied to L-arginine (see above).
Valeriana officinalis (Valerian) root
1. Has been popular for centuries for use in calming upset nerves, and for treating mood problems, pain and headache.
2. One of the most popular antispasmodic medications in Russia and Germany; and Chinese, Asian and North American physicians have incorporated valerian root in their pharmacopoeias.
3. Used in the modern world to treat insomnia, nervous tension, anxiety, muscle cramps, spasms and pain, headache, stress, PMS, menstrual pain and discomfort, hysteria, epilepsy (as an anti-convulsant), autonomic nervous disorders of all kinds (including hypochondria), hypertension, and a wide variety of gastro-intestinal disorders (upset stomach, cramps, colic, gas, flatulence, diarrhea).
4. In herbal terms, it is antispasmodic (muscle relaxant), calmative (sedative, depressant), nervine (tranquilizing), carminative (good for upset stomach and digestion), and anodyne (pain reliever).
5. Is most effective for stress, muscle spasms, nervous exhaustion, headaches with nervous components, heart problems involving nervous tension, insomnia, and even whooping cough.
6. Menstrual pain and discomfort will yield to valerian root best if caused or aggravated by nervousness; high-strung people experiencing PMS will benefit more from valerian root than women whose PMS is more organic in nature.
7. The same applies to gastro-intestinal problems such as dyspepsia and ulcers; valerian targets the nervous system components of these and other conditions.
8. Contains at least three major groups of active constituents: 1) the volatile oil; 2) esters; and 3) alkaloids.
9. The most active components of valerian root, when isolated from the parent plant, are the valepotriates, belonging to the volatile oil group. These are highly unstable substances that tend to degrade rapidly during processing; recently, research, standardization and labeling practices have shifted to the less active, but still effective, valerianic acid (also part of the volatile oil group), along with valeranone and valernal.
10. Is sedative, improves coordination, and antagonizes the hypnotic effects of alcohol.
11. Moderately to strongly sedative in humans, and large doses are not any more effective than small or moderate doses, except in extending the duration of the effect.
12. Increases concentration ability and energy levels.
13. Sedates and regulates the autonomic nervous system in patients and children with control disorders, helps regulate psychosomatic disorders, and helps relieve tension and restlessness.
14. Has neurotropic effects directly on higher centers of the central nervous system.
15. Childhood behavior disorders and learning disabilities are particularly susceptible to the positive effects of valerian root.
16. Useful as a primary sedative for use when sleep disorders are the result of anxiety, nervousness and exhaustion, headache and hysteria; effective in treating tachycardia that just precedes going to sleep.
17. Animals studies have repeatedly shown a sedative action of the root, and clinical trials have confirmed the sedative action in humans of all ages.
18. Reduces nervous disorders, both physical and psychological. That is, it acts as both a sedative and a tranquilizer.
19. Sedates without decreasing reaction time, and can therefore be recommended as a day-time sedative.
20. While the main action of valerian root constituents on the central nervous system is depressant, certain species and/or fractions appear to be mildly stimulating in a minority of people.
21. Possesses an ability to maintain, even improve, motor coordination and mental acuity while simultaneously depressing overall motor activity.
22. Decreases unrest, anxiety and aggressiveness without any decrease in reaction time. These findings match clinical observations in humans.
23. Actually improves reaction time. In human patients with poor concentration ability, valerian has been able to significantly increase performance on several psychological variables.
24. Exhibits a strong sedative action in insomnia and other sleep disorders, with the majority of insomniacs doing quite well, objectively and subjectively.
25. Experimental results indicate that valerian root is at least as effective as small doses of barbiturates and benzodiazepines, without the side effects of the latter substances.
26. Used successfully in the treatment of childhood behavior disorders, including hyperactivity and learning disabilities,
gross nervous restlessness, sleep disorders, headaches, migraines, learning disorders, enuresis, anxiety, and pathological habits such as nail biting and thumb sucking.
27. Helps to stabilize the behavior of psychosomatic patients and patients with other disorders of the autonomic nervous system who exhibit symptoms of anxiety, insomnia, hysteria, ulcers, exaggerated nervousness, PMS, post-menopausal depression, etc. Valerian root products produce a clear increase in performance, coupled with moderate sedation; therefore, patients' motor coordination, concentration ability, reasoning skills and mood increase, but without any hypnotic or depressive symptoms. These effects may be viewed as both psychological and physical stress reduction.
28. In patients diagnosed as having dysregulation of the autonomic nervous system due to various etiologies, valerian extract suppresses and regulates a majority of symptoms, especially restlessness, stress and tension, and produces a mildly relaxing sedative effect.
29. Used to treat certain heart conditions, especially palpitations and arrhythmias; an hypotensive effect has been regularly observed in modern clinical and experimental settings.
30. Produces a direct and distinct relaxation of smooth muscle; this property, combined with a similar action by passion flower, calcium, and magnesium that makes the combination so ideal for dysmenorrhea, PMS and other discomforts associated with the menstrual cycle.
31. Possesses low toxicity. Perhaps one of the most remarkable aspects of valerian root is the almost total lack of toxicity, even with prolonged use. Considering that literally thousands of people have been using these preparations, surprisingly few reports of heartburn, upset stomach, diarrhea, and allergic reactions have come forth. Blood pressure, blood and liver parameters are not influenced. The oral LD50 in rats is an amazingly high 6.8 g/kg. Furthermore, in cats and dogs the oral lethal dose has not been determined because it is so high that that much substance cannot be administered.
One of the main advantages of using valerian is that it has no synergy with alcohol; if alcohol is ingested with conventional tranquilizers the effects combine to produce potentially very dangerous effects. Valerian is free of that danger. Valerian also lacks other commonly experienced side effects of prescription sedative such as Valium and Xanax: depressed coordination; groggy drugged feelings, dependence.
Ginkgo biloba (Ginkgo)
1. Has been called "the doyen of trees," because of its antiquity.
2. Is a complex product or compound, whose method of preparation has become very well-defined and exacting.
3. The active constituents in ginkgo leaves are the flavoglycosides (heterosides), and quercetin, as found in the leaf. These constituents should not be isolated, but should be present in a concentrated extract. Such an extract would be expected to contain about 24% flavoglycosides and 10% quercetin.
4. Successfully protects experimental animals against the destructive effects microscopic particles injected into the carotid artery to mimic arterial blockage.
5. Stabilizes the membranes involved in the blood-brain barrier through a direct action on the ionic potential across the membranes and indirectly, through action on intracellular (mitochondrial) respiration.
6. Inhibits the occurrence of cerebral edema and eliminates its neurological consequences.
7. Inhibits blood platelet aggregation, reduces the tendency for dangerous clots or thrombi to form in veins and arteries and may be of value in the prevention of coronary thrombosis and in recovery from strokes and heart attacks, etc.
8. Neutralizes free radicals, through the action of the flavonoid constituents, including quercetin. Possesses a particular affinity for the central nervous system as well as the adrenal and thyroid glands, and is therefore ideally suited for use in protecting the heart, blood vessels, and brain against the destructive influence of free radicals.
9. Exerts a stimulant effect on the biosynthesis of prostanoids (substances that, among other things, are capable of dilating blood vessels, thereby contributing to the prevention of high blood pressure).
10. Helps prevent the onset and severity of visual impairment due to diabetes, probably because of its effect on free radicals.
11. Improves long distance visual acuity in human patients suffering from senile macular degeneration (macula refers to an opacity of the pupil that occurs in the elderly).
12. Displays a protective effect against argon laser blast-induced lesions of retinal cells; pretreatment with Ginkgo, by capturing the free radicals, prevents significant tissue damage. 
13. Significantly increases blood flow to the brain, and, perhaps more critically, also produces a significant rise in dopamine synthesis, a neurotransmitter that is critical to the transfer of information and electrochemical impulses between nerves and other nerves, and between nerves and muscles, glands, organs, blood vessels and other structures of the body. 14. Because of its capacity to release catecholamines, ginkgo could affect the functioning of the entire network of catecholaminergic, glandular, cardiovascular and nervous systems of the body (perhaps the most extensive network upon which depends the most important functions of life).
15. Exerts a specific effect on the noradrenergic system, as well as on beta-receptors; results in "reactivation" of the aging brain, reverse defects such as memory loss, speech defects, and decrease in alertness.
16. Affects the cholinergic aspect of the nervous system, the decline of which is also implicated in the aging process and the onset of dementia. Increases the population of appropriate cholinergic receptor sites in the brain.
17. Exerts considerable anti-spasmodic or sedative effects, and has excellent restorative effect on the nervous system.
18. Lowers blood pressure and dilates peripheral blood vessels, including the capillaries, in persons recovering from thrombosis.
19. Affects the microcirculation of the conjunctiva in elderly patients suffering from disturbances in cerebral blood supply.
20. Regulatory action makes ginkgo a unique product--at one and the same time able to combat disturbances resulting from vascular spasm, and able, with the same efficiency, to restore tone and circulation in areas subject to vasomotor paralysis.
21. Increases peripheral blood flow without sacrificing cerebral circulation.
22. In patients with peripheral arterial insufficiency, ginkgo produces significant improvement in all experimental measures, including measures of ability to walk long distances without pain, and on blood flow to the legs.
23. Increases blood supply to the brain and improves its nutritional status in patients with Parkinson's disease secondary to cerebral arteriosclerosis.
24. Many dozens of studies have demonstrated ginkgo's ability to improve vascular flow to the brain and elsewhere.(e.g. )
25. Produces definite improvements in alertness measures in persons in whom there is room for improvement but induces no change in the persons whose initial performance is already at a high level.
26. Shows exceptional promise as the drug of choice "in all types of dementia, and even in patients suffering from cognitive disorders secondary to depression, because of its beneficial effects on mood. Of special concern are people who are just beginning to experience deterioration in their cognitive function. Ginkgo biloba extract might delay deterioration and enable these subjects to maintain a normal life and escape institutionalization. In addition, ginkgo biloba extract appears to be a safe drug, being well tolerated, even in doses many times higher than those usually recommended."
Hypericum perforatum (St. John's wort)
1. Possesses a calming, anti-anxiety, mildly sedative action.
2. Has shown good antidepressant action, which is thought to function as a MAO inhibitor.
3. Decreases aggressive behavior, improves symptoms of anxiety, anorexia, depression, insomnia, etc.
1. A source of unsaturated fatty acids that can be utilized by the body to repair and maintain the health of neural tissues.
Pasiflora incarnata (Passion flower)
1. Used primarily as a sedative or nervine to combat excess nervousness and anxiety, to tranquilize, and to promote sleep; as an anodyne, anti-spasmodic and anti-convulsant; it sedates the central nervous system, thus helping to overcome sleeping problems, anxiety, nervousness and more serious conditions such as convulsions and hysteria. It relaxes the smooth muscles, and thereby is useful in the treatment of muscle cramps, asthma, dysmenorrhea, gastro-intestinal problems and bladder dysfunction. 
2. In a recent survey of popular herbal sedatives in Great Britain, passion flower appeared to narrowly outscore valerian root for top honors.
3. Employed as a mild sedative or nervine to help reduce anxiety, nervous tension, hysteria, nervous tachycardia, high blood pressure, and to encourage sleep.
4. Used as an antispasmodic (or spasmolytic) in the treatment of muscle cramps, convulsions, premenstrual tension, and even epilepsy.
5. Helps in overcoming nervous symptoms and cramps that inhibit sleep, and to produce a restful and deep sleep free from frequent awakenings and disturbances.
6. Possesses recognized analgesic or anodyne action.
7. Appears as a proprietary drug for treating neurasthenia, hysteria and abnormal sexual excitability.
8. Used throughout Europe to treat nervous conditions and pain that accompany female complaints ranging from dysmenorrhea, to premenstrual syndrome, to disturbances of menopause.
9. Other uses of passion flower involve the treatment of nervous, high strung, and easily excited children, cardiovascular neuroses, coronary sickness, circulation weakness, and concentration problems in school children.
10. The constituents of passion flower include alkaloids and flavonoids, supported in their actions by a variety of other constituents including amino acids (phenylalanine, tryptophan, glycine, lysine, arginine and tyrosine, among others), sugars, essential oil, oligosaccharides, coumarins (umbelliferone and scopoletin), fatty acids, resin, and steroidal alcohols (e.g. maltol). The alkaloids include passiflorine, passicol, harman, harmalol, harmaline, harmine and harmol. Numbered among the flavonoids are rutin, vitexin, isovitexin, saponarin, isoorenitin, apigenin, luteolin, quercetin and kaempferol.
11. Recently, a glycoside other than the normally iterated flavonoids and alkaloids was found that had the more sedative action than the more common constituents.
12. One report concluded that passion fruit was an ideal substance for use by people caught up in the hectic lifestyles of the modern world, a substance that not only possessed considerable nutritive value, but also possessed extraordinary potential as a tranquilizer.
13. Found in sedative chewing gums in Europe.
14. The best sedative activity has been obtained from a combination of both the flavonoids and the alkaloids as found in the whole herb, rather than either fraction separately.
15. A centrally depressive chemical, a gamma-pyrone derivative called maltol, has been isolated from passion flower and shown to have mild sedative properties in mice.
16. Appears to be completely free of toxicity and side effects, and has been approved by the F.D.A. as a food. No known contraindications exist, but one should use whole plant material, and avoid isolated harmala alkaloids which could be hallucinogenic. Also, it is wise to avoid the use of sympathomimetic agents when using passion flower to treat dysmenorrhea.
1. A source of choline which is the main precursor in the synthesis of acetylcholine.
2. Research suggests that choline supplementation may improve memory, learning and reaction time.
 Kohler, G.O. "The unidentified vitamins of grass and alfalfa." Feedstuffs, August 8, 1953.
 Duke, J.A. CRC Handbook of Medicinal Herbs, CRC Press, Inc., Boca Raton, Florida, 1985.
 Pedersen, M. Nutritional Herbology, Pedersen Publishing, Bountiful, Utah, 1987.
 Bruni, J. Gamma Oryzanol: The Facts, New York, 1988.
 Ishihara, M., et.al., "Clinical effect of gamma oryzanol on climacteric disturbances and serum lipid peroxides." Nippon Sanka Fujinka Gakkai Zasshi, 34(2), 243, 1982.
 von Eickstedt, K.S., et.al.,"Psychopharmacologic effects of valepotriates." Arzneimittel Forschung, 19, 316-319, 1969, AND 19, 993, 1969.
 Schaette, R. Dissertation Muenchen, 1971. and Schaette, R. "Stable valerian preparations." Ger. Offen., 2,230,626, 10 Jan. 1974.
 Boeters, U. "Behandlung vegetativer regulationsstoerungen mit volepotriaten (valmane)." Muenchener Medizinische Wochenschrift, 37, 1873-1876, 1969.
 Straube, C. "The meaning of valerian root in therapy." (In German) Therapie der Gegenwart, 107, 555-562, 1968.
 Wagner, H. "Comparative studies on the sedative action of Valeriana extracts, valepotriates and their degradation products." Planta Medica, 38, 358-65.
 Stoll, A., et.al., "New investigations on valerian." Schweizerische Apotheker Zeitung, 95, 115-120, 1957.
 Hendricks, H., et.al., "Pharmacological screening of valeranal and some other components of the essential oil of valeriana officinalis." Planta Medica, 42, 62-68, 1981.
 Hendriks, H., et.al., "Central nervous system depressant activity of valerenic acid in the mouse." Planta Medica, 49, 28-31, 1985.
 Riedel, et.al., "Inhibition of GABA breakdown by valerenic acid." Planta Medica, 46, 219-220, 1982.
 Hazelhoff, et.al., "Antispasmodic effects of valerian compounds" an in vivo and in vitro study on guinea pig ileum." Archives Internat. de Pharmacoidyn., 257, 274-287, 1982.
 Kempinskas, V. "On the action of valerian." (In Russian) Farmakologiia I Toksikologiia, 4(3), 305-309, 1964.
 Buehring, M. "The effect of valerian-hops preparation on the reaction time of clinic patients." Der Kassenarzt, 16, 1976.
 Stoll, A., et.al., op.cit.
 von Eickstedt, K., et.al., op.cit.
 Hoelzl, J. & Fink, C. "Untersuchungen zur wirkung der valepotriate auf die spontanmotilitaet von maeusen." Arzneimittel-Forschung, 34(1), 44-47, 1984.
 Mayer, B. & Springer, E. Arzneimittel-Forschung, 24K, 2066, 1974.
 Kempinskas, op.cit.
 Broeren, W. Pharmakopsychiatr. Neuropharmakol., 2,1, 1969.
 Leathwood, P.D. & Chauffard, F. "Aqueous extract of valerian reduces latency to fall asleep in man." Planta Medica, 2, 144-148, 1985.
 Leathwood, P.D., Chauffard, F., et.al., "Aqueous extract of valerian root (Valeriana officinalis L.) improves sleep quality in man." Pharmacol. Biochem. & Behav., 17, 65-71, 1982.
 Chauffard, F., et.al., "Detection of mild sedative effects: valerian and sleep in man." Experientia, 37, 622, 1982.
 Leathwood, P.D. & ChaUffard, F., op.cit.
 Klich, R. & Gladbach, B. "Verhaltensstoerungen im kindesalter und deren therapie." Medizinische Welt, 26(25), 1252-1254, 1975.
 Broeren, op.cit.
 Straube, G., 1968, op.cit.
 Buchtala, M., Hippokrates,12, 466-468, 1969.
 Moser, L. "Medicine for stress behind the wheel?" Deutsche Apotheker Zeitung, 121, 2651-2654, 1981.
 Boeters, U., 1969, op.cit.
 Petkov, V. & Manolov, P. "Pharmacological studies on substances of plant origin with coronary dilating and antiarrhythmic action." Comparative Medicine East and West, 6(2), 123-130, 1978.
 Mirnov, V.N. "Blood coagulation changes under the effect of valerian officinalis." (In Russian) Farmakologiia I Toksikologiia, 29, 187-188, 1966.
 Hanak, T. "Phytotherapie in der kardiologischen alltagspraxis." Zhurnal der Allgemein Medizin, 56, 276-283, 1980.
 Kempinskas, V. op.cit.
 Zburzhinksy, V.K. "An investigation into the sedative effect of valerian." (In Russian) Farmakologiia I Toksikologiia, 27(3), 301-305, 1964.
 Manolova, P. & Petkov, V. "Screening studies on valepotriatic fractions from valerian officinalis roots." Farmazia, 26(2), 29-34, 1976.
 Petkov, V.D., et.al., "Pharmacological studies of a mixture of valepotriates isolated from valerian officinalis." Dokl. Bolg. Akad. Nauk, 27, 1007-1010, 1973.
 Houghton, P. "The biological activity of valerian and related plants." Journal of Ethnopharmacology, 22, 121-142, 1988.
 List, P.H. & Hoerhammer, L. Hager's Handbuch der Pharmazeutischen Praxis. Berlin, Springer-Verlag, 1979.
 Dziuba, K. Medizinische Welt, 1968, pp. 1866-1868.
 reported in Klich, R. & Gladbach, B. "Verhaltensstoerungen im kindesalter und deren therapie." Medizinische Welt, 26(25), 1252-1254, 1975.
 Drieu, K. "Preparation et definition de l'extrait de ginkgo biloba." Presse Med., 15(31), 1455-7, 1986.
 Larsen, R.G., Dupeyron, J.P., Boulu, R.G., "Modele d'eschemie cerebrale experimentale par microspheres chez le rat. Etude de l'effect de deux extraits de ginkgo biloba et du naftidrofuril." Therapie, 33, 651, 1978.
 Rapin, J.R. & Le Poncin-Lafitte, M. "Modele experimental d'ischemie cerebrale. Action preventive de l'extrait de ginkgo." Sem. Hop. Paris, 55, 2047, 1979.
 Le Poncin-Lafitte, M., Rapin, J., Rapin J.R. "Effects ofginkgo biloba on changes induced by quantitative cerebral microembolization in rats." Arch. Int. Pharmacodyn., 243, 236, 1980.
 Rapin, J.R. & Le Poncin-Lafitte, M. "Consommation cerebrale du glucose. Effet de l'extrait de ginkgo biloba." Presse Med., 15(31), 1494-7, 1986.
 Grosdemouge, C, Le Poncin-Lafitte, & Rapin, J.R. "Effets protecteurs de l'extrait de ginkgo biloba sure la rupture precoce de la barriere hemoencephalique le rat." Presse Med., 15(31), 1502-1505, 1986.
 Spinnewyn, B., Blavet, N. & Clostre, F. "Effets de l'extrait de ginkgo biloba sure un modele d'ischemie cerebrale chez lagerbille." Presse Med., 15(31), 1511-1986.
 Etienne, A., Hecquet, F. & Clostre, F. "Mecanismes d'action de l'extrait de ginkgo biloba sure l'oedeme cerebral experimental." Presse Med., 15(31), 1506-1510, 1986.
 Borzeix, M.G., Labos, M. & Hartl, C. "Recherché sure l'action antiagregant de l'extrait de ginkgo biloba. Activite auniveau des arteres et des veines de la pie-mere chez le lapin." Arch. Int. Pharmacodyn., 243, 236, 1980.m
 Brunello, N., Racagni, G., Clostre, F., Drieu, K., & Braquet, P., "Effects of an extract of ginkgo biloba on noradrenergic systems of rat cerebral cortex." Pharm. Res. Commun., 17, 1063-72, 1985.
 Pincemail, J. & Deby, C. "Proprietes antiradicalaires de l'extrait de ginkgo biloba." Presse Med., 15(31), 1475-9, 1986.
 Doly, M., Droy-Lefaix, M.T., Bonhomme, B. & Braquet, P. "Effet de l'extrait de ginkgo biloba sur l'electrophysiologie de la retine isolee de rat diabetique." Presse Med., 15(31), 1480-3, 1986.
 Lebuissen, D.A., Leroy, L. & Rigal, G. "Traitement des degenerescences 'maculaires seniles' par l'extrait de ginkgo biloba. Etude preliminaire a double insu face au placebo." Presse Med., 15(31), 1556-8, 1986.
 Clairambault, P., Magnier, B., Droy-Lefaix, M.T., Magnier, M., & Pairault, C., "Effet de l'extrait de ginkgo biloba sur les lesions induites par une photocoagulation au laser a l'argon sur la retine de lapin." Sem. Hop. Paris, 62, 57, 1986.
 Le Poncin-Lafitte, M., Martin, P., Lespinasse, P., & Rapin, J.R., "Ischemie cerebrale apres ligature non simultanee des arteres carotides chez le rat: effet de l'extrait de ginkgo biloba." Sem. Hop. Paris, 58, 403, 1982.
 Auguet, M., De Feudis, V., Clostre, F. & Deghenghi, R. "Effects of an extract of ginkgo biloba on rabbit isolated aorta." Gen. Pharmac., 13, 225, 1982.
 Racagni, G., Brunello, N. & Paoletti, R. "Neuromediatorchanges during cerebral aging. The effect of ginkgo biloba extract." Presse Med., 15(31), 1488-90, 1986.
 Taylor, J.E. "Liasions des neuromediateurs a leurs recepteurs dans le cerveau de rats. Effet de l'administration chronique de l'extrait de ginkgo biloba." Presse Med., 15(31), 1491-3, 1986.
 Montanini, R. & Gaspari, G. "Impiego di un estratto di ginkgo biloba (TEBONIN) nella terrapia delle vasculopatie cerebrali." Min. Card., 17, 1096, 1969.
 Trounier, H. "Klinish-pharmakologische untersuchungen ueber den effect eines extraktes aus ginkgo biloba L. beim postthrombotischen syndrom." Arzneimittel Forschung, 18, 551, 1968.
 Massoni, G., Piovella, C & Fratti, L. "Effets microcirculatoieres de la ginkgo biloba chez les personnesagees." Giorn. Geront., 20, 444, 1972.
 Piovella, C. "Effetti della ginkgo biloba sui micorovasi della congiuntiva bulbare." Minerva Med., 64, 4179, 1973.
 Auguet, M. et. al., op. cit., 1986.
 Galley (Yatley?), P. & Safi, N. "Tanakan et cerveau senile. Etude radiocirculographique." Bordeaux Med., 10, 171, 1977.
 Bauer, U. "6-month double blind randomized clinical trial of ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency." Arzneimittel Forschung, 34, 716, 1984.
 Hemmer, R. & Tzavellas, O. "Zur zerebralen wirksamkeit eines pflanzen praparates aus ginkgo biloba." Arzneimittel Forschung, 17, 491, 1967.
 Boudouresques, G., Vigourous, R., Boudouresques, J. "Interet et place de l'extrait de ginkgo biloba en pathologie vasculaire cerebrale." Medicine Praticienne, 55-75, 1975.
 Moreau, Ph. "Un nouveau stimulant circulatoiere cerebral." Nouv. Presse. Med., 4, 2401, 1975.
 Haan, J., Reekermann, V., Welter, F.L., Sabin, G. & Muller, E. "Ginkgo biloba flavonglykoside. Therapie moglichkeit der zerebralen insuffizienz." Medizinische Welt, 33, 1001, 1982.
 Gessner, B., Voelp, A. & Klasser, M. "Study of the long- term action of a ginkgo biloba extract on vigilance and mental performance as determined by means of quantitative pharmaco-EEG and psychometric measurements." Arzniemittel Forschung, 35(9), 1459-1465, 1985.
 Hindmarch, I. & Subhan, Z. Clin. Pharmacol. Res., 4, 89, 1980.
 Hindmarch, I. "Activite de l'extrait de ginkgo biloba sur la memoire a court terme." Presse-Med., 15(31), 1592-4, 1986.
 Pidoux, B. "Effets sure l'activite fonctionnelle cerebrale de l'extrait de ginkgo biloba. Bilan d'etudes cliniques et experimentales." Presse Med., 15(13), 1588-91, 1986.
 Dehen, H., Dordain, G. & Allard, M. "Methodologie d'un essai controle dans la maladie d'Alzheimer." Presse Med., 15(31), 1577-82, 1986.
 Allard, M. "Traitment des troubles du vieillissement par extrait de ginkgo biloba." Presse Med., 15(31), 1540-5, 1986.
 Warburton, D.M. "Psycho-pharmacologie clinique de l'extrait de ginkgo biloba." Presse Med., 15(31), 1595-604, 1986.
 Suzuki, O., et.al., "Inhibition of monoamine oxidase by hypericin." Planta Medica, 50, 272-274, 1984.
 Okpanyi, S.N. & Weischer. "Tierexperimentelle untersuchungen zur psychotropen wirksamkeit eines hpericum extraktes." Arzneim. Forsch., 37, 10-13, 1987.
 Muldner, H. & Zoller, M. "Antidepressive wirkung eines auf den wirkstoffkomplex hypercin standardisierten hypericum extraktes." Arzneim. Forsch., 34, 918, 1984.
 Lutomski, J., Segiet, E., Szpunar, K & Grisse, K. "Die bedeutung der passionsblume in der heilkunde." Pharmazie in Unserer Zeit, 10(2), 45-49, 1981.
 Phillipson, J.D. & Anderson, L.A. Pharmaceutical Journal, 2, 80, 1984 (review article).
 Aoyagi, N., Kimura, R. & Murata, T. Chemical & Pharmaceutical Bulletin, 22, 1008-1013, 1974.
 Ross, M.S.F. & Anderson, L.A. "Selection of plants for phytopharmacological study based on modern herbal practice." International Journal of Crude Drug Research, 24(1), 1-6, 1986. (Valerian & passion flower were most popular; valerian was listed first, but passion flower had the greater point total, so it is questionable which is truly the greater.)
 Neu, R. "Inhaltsstoffe der passiflora incarnata. 1." Arzneimittel-Forschung, 4, 292-294, 1954; and 6, 94-98, 1956.
 Schindler, H. "Die inhaltsstoffe von heilpflanzen undpruefungsmethode fuer pflanzliche tinkturen." Arzneimittel-Forschung, 5, 491-492, 1955.
 Lutomski, J., Malek, B. & Rybacka, L. "Pharmacochemical investigation of the raw materials from passiflora genus. 2. The pharmacochemical estimation of juices from the fruits of passiflora edulis and passiflora edulis forma flavicarpa." Planta Medica, 27, 112-121, 1975.
 Ambuehl, H. "Anatomische und chemische untersuchungen an passiflora coerula L. und passiflora incarnata L." Dissertation Number 3830, ETH Zurich, 1966.
 Planta Medica, 54(6), 488-491, 1988.
 Lutomski, J., et.al., 1975, op.cit.
 Gagiu, F, Budiu, T, Lavu, P. & Bidiu, O. Romanian patent #59,589; (Chem Abstracts 89, 48897n, 1978).
 Lutomski, J. & Wrocinski, T. "Pharmacodynamic properties of passiflora incarnata preparations. The effect of alkaloid and flavonoid components on pharmacodynamic properties of the raw material." Biul. Inst. Roslin Leczniczych, 6, 176-184, 1960.
 Aoyagi, N., et.al., op.cit.
 Glotzbach, B. & Rimpler, H. "Die flavonoide von passiflora incarnata L., passiflora quadrangularis L., und passiflora pulchella H.B.K." Planta Medica, 16, 1-7,